Currently, the share price for Concord Drugs Ltd. is delayed. Login to view live prices.
Concord Drugs Ltd.
-- ( -- %) 1D
- Prev. Close36.11
- Upper Circuit44.53
- Lower Circuit29.69
Concord Drugs Ltd.'s Info & Management
Concord Drugs is engaged in manufacture licensed drugs based on the formulations approved.
- Company Secretary,Compliance OfficerS Nagi Reddy
- Executive Director,Whole Time Director,Chief Financial OfficerKoni Reddy
- Production Manager(Tablets)V. Phani Sekhar
- General ManagerB. Venugopal Reddy
- Production Manager(Medical)M.Rameswar Reddy
- Chemist(Tablets)K. Krishna Prasad
FAQs on Concord Drugs Ltd.
What is the share price of Concord Drugs Ltd.?
Concord Drugs Ltd. share price is ₹37.20 as of December 8, 2023, 03:25 PM. Share/stock prices are volatile and change over the course of a trading day, and may differ basis on exchange (NSE/BSE).
What is the 52-week high and low of Concord Drugs Ltd.?
The 52-week high and low of Concord Drugs Ltd. is ₹41.80 and ₹24.80 respectively as of December 8, 2023, 03:25 PM. 52-week high and low represent the maximum and minimum value of the share price respectively, over the last 52 weeks (similar to 1 year).
What is the PE ratio of Concord Drugs Ltd.?
The PE ratio of Concord Drugs Ltd. is 22.60 as of December 10, 2023.The PE ratio measures the current share price relative to the earnings of the company for past 12 months (as of last reported period).
What is the PB ratio of Concord Drugs Ltd.?
The trailing twelve month (TTM) PB ratio of Concord Drugs Ltd. is 1.10 as of December 10, 2023. The PB ratio measures the market capitalization of the company relative to it’s book value (carrying value on the balance sheet) as of last reported period.
What are the Upper Circuit and Lower Circuit of Concord Drugs Ltd.?
The Upper Circuit of Concord Drugs Ltd. is ₹44.53. The Lower Circuit of Concord Drugs Ltd. is ₹29.69.
What is the ROE of Concord Drugs Ltd.?
Concord Drugs Ltd. reported an ROE of 2.81% for the last reported financial year on a consolidated account basis. Return on Equity (ROE) reflects how efficiently the company is able to generate profit as a percent of their equity financing.
What is the shareholding pattern of Concord Drugs Ltd.?
Shareholding pattern gives insights on the concentration of holdings towards various groups of investors. As of last reported quarter for Concord Drugs Ltd., Promoter held 52.1%, and the public held 47.9% of the total shares.
How to buy Concord Drugs Ltd. Share?
What is the fair value of Concord Drugs Ltd.?
The fair value of Concord Drugs Ltd. is an estimated price at which buyers and sellers would freely trade their shares. The various ways to determine the fair value of an asset include looking at recent market transactions for similar assets, estimating its expected earnings or the cost of replacing it.
Trademarks owned by their respective owners and shown here only for ease of recall of the respective owner by public.